文献速递泌尿生殖技术与安全PETCT

前列腺特异性膜抗原PET:转移性前列腺癌的治疗反应评估

Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer.
PubMed 文献 · Radiographics · 2020-08-07

本文综述了前列腺特异性膜抗原(PSMA)PET在转移性前列腺癌治疗反应评估中的作用。传统影像评估存在无法检出小体积病灶、骨病灶不可测量及依赖PSA等局限。PSMA PET在多种治疗(转移灶定向治疗、雄激素剥夺治疗、化疗、放射性核素治疗、免疫治疗)反应评估中与PSA水平和临床结局有良好相关性,但不同治疗对PSMA表达的影响可导致判读陷阱,放射科医生需了解。

要点

  • PSMA PET在转移性前列腺癌治疗反应评估中与PSA水平及临床结局有良好相关性。
  • 雄激素剥夺治疗和免疫治疗可影响前列腺癌细胞PSMA表达,导致判读不准。
  • 传统影像(CT、骨扫描)无法检出小体积病灶且骨病灶不可测量,PSA为传统首选生物标志物。

诊断标准与关键数值

  • 前列腺癌主要采用前列腺癌工作组3(PCWG3)标准。
  • 实体瘤疗效评价标准(RECIST)是肿瘤学中基于数据的可重复指南最成功的范例。

临床应用与阅片要点

  • PSMA PET在多种转移性前列腺癌治疗(转移灶定向治疗、雄激素剥夺治疗、化疗、放射性核素治疗、免疫治疗)反应评估中的作用仍在演变。
  • 放射科医生必须了解雄激素剥夺治疗和免疫治疗对前列腺癌细胞PSMA表达的特异性影响及由此产生的潜在陷阱和不准确性。
  • 新兴数据显示PSMA PET与PSA水平和临床结局有良好相关性。

局限性

  • 传统影像评估转移性前列腺癌存在局限:无法检出小体积病灶、骨(不可测量)病灶在影像上高发、血清PSA水平作为反应评估和疾病进展首选生物标志物的既定作用。
  • 每种治疗(尤其是雄激素剥夺治疗和免疫治疗)对前列腺癌细胞PSMA表达有特异性影响,可能导致潜在陷阱和不准确性。
  • 尽管存在一些局限性,PSMA PET正在弥补传统影像方法和非影像生物标志物在转移性前列腺癌治疗反应评估中的不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Therapy response assessment is a critical step in cancer management, leading clinicians to optimize the use of therapeutic options during the course of the disease. Imaging is a pivotal biomarker for therapy response evaluation in oncology and has gained wider use through the development of reproducible data-based guidelines, of which the Response Evaluation Criteria in Solid Tumors is the most successful example. Disease-specific criteria have also been proposed, and the Prostate Cancer Working Group 3 criteria are the mainstay for prostate cancer (PC). However, conventional imaging evaluation in metastatic PC has several limitations, including (a) the inability to detect small-volume disease, (b) the high prevalence of bone (nonmeasurable) lesions at imaging, and (c) the established role of serum prostate-specific antigen (PSA) levels as the biomarker of choice for response assessment and disease progression. In addition, there are an increasing number of newer treatment options with various effects on imaging features. Prostate-specific membrane antigen (PSMA) PET has improved patient selection for newer treatments, such as metastasis-directed therapy (MDT) or radionuclide therapy. The role of PSMA PET in response assessment for many metastatic PC therapeutic options (MDT, androgen deprivation therapy, chemotherapy, radionuclide therapy, and immunotherapy) is an evolving issue, with emerging data showing good correlation with PSA levels and clinical outcome. However, there are specific implications of each therapy (especially androgen deprivation therapy and immunotherapy) on PSMA expression by PC cells, leading to potential pitfalls and inaccuracies that must be known by radiologists. Despite some limitations, PSMA PET is addressing gaps left by conventional imaging methods (eg, CT and bone scanning) and nonimaging biomarkers (PSA levels) in metastatic PC therapy response assessment, a role that can be improved with advances like refinement of interpretation criteria and whole-body tumor burden quantification.© RSNA, 2020See discussion on this article by Barwick and Castellucci.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Barbosa FG, Queiroz MA, Ferraro DA, et al. Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer. Radiographics. 2020. PMID: 32762625. doi:10.1148/rg.2020200058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。